This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08928/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08928/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08928/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08928
rdf:type
n5:Drug
n5:description
Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite) and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years latter by Endo Products (Balarsen, Tablets, 0.1 g). Among trivalent organoarsenicals, arthinol was considered as very well tolerated. Recently, it was studied for its anticancer activity. [Wikipedia]
n5:generalReferences
# Cristau B, Chabas ME, Placidi M. (1975) Voies et cinétiques d'excrétion de l'arsenic chez le Cobaye après injection de divers médicaments organo-arséniés. Ann Pharm Fr 33: 577-89
n5:group
approved
n5:indication
Antiprotozoal agent effective against amoebiasis and yaws.
owl:sameAs
n9:DB08928
dcterms:title
Arsthinol
adms:identifier
n4:DB08928 n7:D07356 n10:Arsthinol
n5:synonym
Arsthinenol
n5:toxicity
Oral,mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat: LD50 = 980 mg/kg.
n5:IUPAC-Name
n6:271B5D84-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5D8A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5D89-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5D86-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5D87-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5D88-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5D83-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:P01AR01
n5:H-Bond-Acceptor-Count
n6:271B5D90-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5D91-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5D8B-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5D8C-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5D8E-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5D8D-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5D8F-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Protozoa
n5:casRegistryNumber
119-96-0
n5:Bioavailability
n6:271B5D96-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5D98-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5D99-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5D95-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5D94-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5D97-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5D85-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5D92-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5D93-363D-11E5-9242-09173F13E4C5